Skip to main content
Ocugen, Inc. logo

Ocugen, Inc. — Investor Relations & Filings

Ticker · OCGN ISIN · US43358V1098 LEI · 549300JVNUI9CXWJLR09 US Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2014-11-26 Capital/Financing Update
Country US United States of America
Listing US OCGN

About Ocugen, Inc.

https://ocugen.com/

Ocugen, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing novel gene therapies, cell therapies, and vaccines. The company's primary mission is to develop treatments for blindness diseases, leveraging its first-in-class modifier gene therapy platform. This platform represents a potential paradigm shift in treating inherited retinal diseases by aiming to address multiple genetic mutations with a single product. In addition to its focus on ocular health, Ocugen is also advancing a pipeline that includes vaccines for infectious diseases. The company is dedicated to addressing significant unmet medical needs and providing innovative therapeutic options for patients with debilitating conditions.

Recent filings

Filing Released Lang Actions
FWP
Capital/Financing Update Classification · 95% confidence The document is an Issuer Free Writing Prospectus (FWP) filed pursuant to Rule 433 of the Securities Act of 1933, relating to a preliminary prospectus for a securities offering. It discusses clinical trial data and references a registration statement filed with the SEC but not yet effective. The text includes detailed clinical trial results and scientific articles but is primarily a marketing and disclosure document related to a securities offering, not a financial report or regulatory filing of financial results. It is not an Annual Report, Earnings Release, or any other financial report type. The document is a prospectus supplement or free writing prospectus, which is a type of capital markets disclosure related to financing activities. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length and content support this classification with high confidence.
2014-11-26 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 3 to a Form S-1 Registration Statement filed with the SEC. It includes detailed information about securities registration, indemnification of directors and officers, recent sales of unregistered securities, and exhibits related to the registration. Form S-1 is a registration statement used for initial public offerings (IPOs) and other securities offerings, which falls under capital raising and financing activities. The document is not a financial report, earnings release, or management discussion but a regulatory filing related to capital issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a certification but a substantive filing related to capital raising.
2014-11-26 English
8-A12B
Regulatory Filings Classification · 95% confidence The document is a Form 8-A filed with the SEC, which is used for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It includes details about the registration of common stock on NASDAQ and references a related Form S-1 registration statement. The document is a regulatory filing related to securities registration, not a financial report, earnings release, or other specific report types. It is a formal regulatory announcement of securities registration, fitting the category of Regulatory Filings (RNS). The document length is under 5,000 characters and it is a standalone filing form, not a report or announcement of a report publication.
2014-11-18 English
S-1/A
Regulatory Filings Classification · 95% confidence The document is a Form S-1/A Registration Statement Amendment No. 2 filed with the SEC, dated November 14, 2014, for Histogenics Corporation. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of common stock. The text includes detailed prospectus information such as risk factors, business overview, management discussion, financial information, and underwriting details. This type of filing is a registration statement for securities offering, which is distinct from annual reports, earnings releases, or other financial reports. The S-1/A is an amendment to the initial S-1 registration statement, used to update or correct information before the IPO becomes effective. According to the provided filing categories, none directly correspond to an S-1 registration statement or IPO prospectus. The closest relevant category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous filings that do not fit other categories. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or certification but a substantive regulatory filing.
2014-11-14 English
S-1/A
Capital/Financing Update Classification · 95% confidence The document is a Form S-1/A Registration Statement filed with the SEC, which is used for registering securities for an initial public offering (IPO). It includes detailed information about the company, its business, risk factors, management, financials, and the offering itself. This type of filing is neither an annual report, earnings release, nor a management or board announcement. It is a capital markets filing related to the company's public offering of shares. According to the provided filing definitions, updates on company fundraising or financing activities fall under Capital/Financing Update (CAP). Since this is an amended registration statement for an IPO, it is best classified as a Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, not just an announcement or notice, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2014-11-07 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a detailed correspondence letter from Histogenics Corporation to the SEC regarding their Registration Statement on Form S-1, which is related to their initial public offering (IPO). The letter discusses stock-based compensation, valuation methodologies, estimated offering price, and market conditions affecting the IPO. It references the Registration Statement and provides detailed responses to SEC comments, including confidential treatment requests. This type of document is a regulatory correspondence related to a registration statement filing, not a financial report, earnings release, or other report types. It is not a report publication announcement since it contains substantive discussion and analysis rather than just announcing a report's availability. The document fits best under Regulatory Filings (RNS) as it is a regulatory correspondence responding to SEC comments on a registration statement.
2014-10-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.